U-Blot® Research Grade Vunakizumab

U-Blot® Research Grade Vunakizumab
U-Blot® Research Grade Vunakizumab
$9,999.00
Size:50ug
SKU: WA3807-50

Catalog No.: WA3807

Specification: 50ug/100ug

Stock: In stock

U-Blot® Research Grade Vunakizumab Learn more

Product information

U-Blot® Research Grade Vunakizumab

Product Overview

Catalog No.
WA3807
SKU
WA3807-50
Category
Biosimilar Antibodies
Product Type
Other
Size
50ug/100ug
Stock Status
In stock
Available Stock
999
Minimum Order Quantity
1

Storage & Compliance

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Research Use Only
Yes

Additional Specifications

PackSize
50ug/100ug
Target
CTLA-8
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host Species
Humanized
Isotype
IgG1-kappa
Conjugate/Modification
--
Recommended Dilution Ratio
--
Composition
0.01M PBS, pH 7.4.
Purification Process
Protein A/G purified from cell culture supernatant.
Purity
>95% as determined by SDS-PAGE.
storageCondition
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clonality
Monoclonal
Clone Number
--
Immunogen
Mammalian Cells
Alias
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A
Species
--
Gene ID-1
Q16552
Uniprot
--
Background
Ixekizumab is a humanized monoclonal antibody to interleukin-17A which acts as an antiinflammatory agent and is used to treat moderate-to-severe plaque psoriasis. Ixekizumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury.<br>• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781<br/>• Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability., PMID:26431948<br/>• IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment., PMID:37579542<br/>• The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases., PMID:34863654<br/>• IL-17 for therapy., PMID:28633806<br/>• Association Between., PMID:35271496<br/>• Vunakizumab: First Approval., PMID:39497021<br/>• The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies., PMID:31278139<br/>• IL-17A Modulates Peritoneal Macrophage Recruitment and M2 Polarization in Endometriosis., PMID:32117261<br/>• Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F., PMID:32973785<br/>
Tissue Expression
--
Signaling_pathway
--
Research Areas
--

Tech Support

ucallm

01

Documents

Datasheet, COA, SDS, and protocol files can be requested from technical support.

02

Storage & Handling

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
06

Contact Support

Emailinfo@mail.ucallm.com

Phone+(1)-866-986-9598

WeChat / IMUcallm-Tech

HoursMonday-Friday 09:00-18:00 CST

Request Technical Support
Keywords:Biosimilar Antibodies